Sur180 Therapeutics

We know that for many women living with endometriosis, this day brings mixed emotions. The impact of this disease on fertility is real, and we do not take that lightly.

At Sur180 Therapeutics, preserving fertility is not just a scientific goal. It is at the heart of everything we are building.

We are working on a non-hormonal treatment that targets the disease without compromising your reproductive choices.

Because every woman deserves options.

🔗 www.sur180therapeutics.com

May is Women's Health Month and there is no better time to talk about endometriosis.

An estimated 190 million women worldwide live with this disease. Most wait on average 7 to 10 years for a diagnosis. Current treatments fall short of what patients truly need.

At Sur180 Therapeutics, we are working to change that. Our team is developing a novel non-hormonal treatment for endometriosis that targets the disease without compromising fertility.

This is our mission. Every month. Every day.

🔗 www.sur180therapeutics.com

Most current treatments for endometriosis work by suppressing the hormonal system. For women who want to preserve their fertility, this creates a significant challenge.

✅Hormonal birth control masks symptoms but does not treat the underlying disease
✅GnRH agonists induce a temporary menopausal state, causing bone loss, mood changes, and severe depression that many patients cannot sustain
✅Surgery provides temporary relief but endometriosis frequently returns
✅No current treatment safely manages the disease across the full years between onset and natural menopause

This is the gap Sur180 Therapeutics is working to address. We are developing a non-hormonal treatment that targets the root of the disease without interfering with fertility.

www.sur180therapeutics.com

Sur180 Therapeutics

Research suggests that up to 50% of women with endometriosis experience infertility. However, the most widely used treatments are hormonal, and for women who want to preserve their fertility, that creates a difficult choice between managing the disease and protecting their ability to conceive.

Early diagnosis and treatments that do not compromise fertility are critical. At Sur180 Therapeutics, preserving fertility is at the center of our research.

www.sur180therapeutics.com

Source: Bulletti et al., Journal of Assisted Reproduction and Genetics, 2010.

Sur180 Therapeutics

On the International Day of Maternal Health and Rights, we advocate for every woman's right to make informed decisions about her reproductive health.

Endometriosis is one of the leading causes of infertility in women of reproductive age. However, most available treatments suppress hormones and carry risks that directly impact a woman's ability to conceive, leaving many patients without a safe option that respects their reproductive choices.

Every woman deserves treatments that address her disease without compromising her fertility. At Sur180 Therapeutics, this is not just a scientific goal. It is a commitment.

www.sur180therapeutics.com

On World Health Day, we reaffirm our mission.

Endometriosis affects more than 190 million women worldwide, yet it remains underdiagnosed, undertreated, and underfunded.

No woman should wait 7 to 10 years for an answer or be forced to choose between managing pain and preserving fertility.

At Sur180 Therapeutics, we are working to change that.

www.sur180therapeutics.com

Source: World Health Organization (2023). www.who.int/news-room/fact-sheets/detail/endometriosis

Endometriosis pain is often minimized or dismissed, but it is real, life-altering, and deserves proper recognition.

At Sur180 Therapeutics, we are committed to developing non-hormonal therapeutics aimed at improving long-term pain management.

We hear you, we believe you, and we are working toward better solutions.

🔗 www.sur180therapeutics.com

Our Co-Founder and Chair of the Scientific Board, Idhaliz Flores, Ph.D., has been honored with the SRI Distinguished Scientist Award by the Society for Reproductive Investigation at their 73rd Annual Scientific Meeting in San Juan, Puerto Rico.

This recognition reflects her more than 25 years of research dedicated to advancing the understanding of endometriosis, pelvic pain, and reproductive health.

At Sur180 Therapeutics, we are proud of her achievements and the research she has dedicated to advancing solutions for patients.

🔗 www.sur180therapeutics.com

Today we celebrate the doctors who stand beside endometriosis patients. From early evaluation to long-term management, your care changes lives.

Thank you for listening, advocating, and working tirelessly to improve the future of endometriosis care.

🔗 www.sur180therapeutics.com

Exploring what the future of endometriosis care could look like. If you’re interested in learning more, feel free to get in touch.